Phase 1 Prevention Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Influenza PreventionPandemic Influenza Prevention
National Institute of Allergy and Infectious Diseases (NIAID)56 enrolled1 locationNCT07111078
Recruiting
Phase 1
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
Colorectal AdenomaColorectal Cancer Prevention
Massachusetts General Hospital20 enrolled1 locationNCT07095517
Recruiting
Phase 1
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Influenza PreventionSeasonal Influenza
National Institute of Allergy and Infectious Diseases (NIAID)45 enrolled1 locationNCT06863142
Recruiting
Phase 1
Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers
Healthy VolunteerHIV Prevention
Johns Hopkins University24 enrolled1 locationNCT07349758
Recruiting
Phase 1Phase 2
Aging and Task-specific Training to Reduce Falls
Fall Prevention
University of Illinois at Chicago315 enrolled1 locationNCT07094659
Recruiting
Phase 1Phase 2
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Prevention of Rejection in Kidney Transplant
Eledon Pharmaceuticals48 enrolled9 locationsNCT05027906
Terminated
Phase 1
A pilot 2-way crossover pharmacokinetic (PK) study (Part A) followed by a pivotal 2-way crossover PK study to assess bioequivalence (Part B) between a test and reference intravenous formulations of 150 mg Fosaprepitant
prevention of nausea and vomiting caused by Chemotherapy
Nevakar Inc56 enrolled1 locationACTRN12619000189123
Completed
Phase 1
Single Ascending Dose Study to Evaluate the Safety and Tolerability of LPT99 Administered to Healthy Adult Subjects
Prevention of Hearing loss
Spiral Therapeutics, Inc.32 enrolled1 locationACTRN12618001461280
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of ferrous sulfate/sodium ascorbate modified release tablet against the innovator ferrous sulfate/sodium ascorbate modified release tablet conducted under fasting conditions with diet control in healthy male volunteers
Iron deficiency.
Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, ferrous sulfate and vitamin C is an iron supplement indicated for the prevention and treatment of iron deficiency.
Zenith Technology Corp Ltd24 enrolled1 locationACTRN12618000222246
Recruiting
Phase 1
An open-labeled, randomized, crossover, single-dose study in healthy male subjects to test the pharmacokinetics (how your body handles the drug e.g. how it absorbs it and how it eliminates it), safety, and tolerability of investigational drugs taken as single agents or as combinations of two investigational drugs, with a pharmacokinetics comparison to the marketed drug Reyataz(Registered Trademark)
treatment and prevention of HIV
Concert Pharmaceuticals, Inc32 enrolled1 locationACTRN12610001080011
Completed
Phase 1
Fibre, protein and insulin resistance diet study
Insulin resistance in healthy overweight women.Metabolic syndrome in healthy overweight women.Diabetes prevention in healthy overweight women.
Dr Kirsten McAuley72 enrolled1 locationACTRN12607000154404
Completed
Phase 1
Interactions between herbal medicines and the anticoagulant warfarin
Drug interactions of warfarin with herbal medicines in healthy male subjects. Relevant to Stroke prevention and people receiving warfarin
Prof Andrew McLachlan60 enrolled1 locationACTRN12607000054415
Not Yet Recruiting
Phase 1
Physician Preference/ Performance Evaluation of F.A.S.T.-LVG for the Temporary Occlusion of Blood Flow in Patients During Interventional Procedures in Saphenous Vein Grafts and Coronary Arteries
Prevention/reduction of release or movement of potentially embolic debris from the treatment area and aspiration of such debris prior to blood flow restoration.
Genesis Medical Interventional, Inc.60 enrolled1 locationACTRN12605000277640